Highlighted Advances in Therapies for Difficult-To-Treat Brain Tumours Such as Glioblastoma
Glioblastoma multiforme (GBM) remains a challenging disease, as it is the most common and deadly brain tumour in adults and has no curative solution and an overall short survival time. This incurability and short survival time means that, despite its rarity (average incidence of 3.2 per 100,000 pers...
Main Authors: | Nuno Cruz, Manuel Herculano-Carvalho, Diogo Roque, Cláudia C. Faria, Rita Cascão, Hugo Alexandre Ferreira, Catarina Pinto Reis, Nuno Matela |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-03-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/15/3/928 |
Similar Items
-
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
by: Xin Wang, et al.
Published: (2019-02-01) -
Electrotherapies for Glioblastoma
by: Elise P. W. Jenkins, et al.
Published: (2021-09-01) -
Nanoparticle-Based Treatment in Glioblastoma
by: Diogo Roque, et al.
Published: (2023-08-01) -
Targeting the Endocannabinoid System Present in the Glioblastoma Tumour Microenvironment as a Potential Anti-Cancer Strategy
by: Mendhi Henna Dasram, et al.
Published: (2024-01-01) -
The Role of Progranulin (PGRN) in the Pathogenesis of Glioblastoma Multiforme
by: Łukasz A. Poniatowski, et al.
Published: (2024-01-01)